Chronic graft versus host disease affecting the skin is a serious complication that can develop after a bone marrow or stem cell transplant, where the donor’s immune cells mistakenly attack the recipient’s body, particularly affecting the skin and often changing the quality of life for transplant survivors.

What Is Chronic Graft Versus Host Disease in Skin

Chronic graft versus host disease in skin, often shortened to chronic GVHD, is a medical condition that can occur after someone receives a stem cell transplant or bone marrow transplant from another person. In this type of transplant, called an allogeneic transplant, a patient receives healthy stem cells from a donor to replace their own damaged or diseased cells. These transplants are commonly used to treat serious blood cancers and other blood disorders.^[1]

What makes chronic GVHD so challenging is that the donated immune cells, which are meant to help the patient, begin to see the patient’s own body tissues as foreign invaders. The donor cells essentially launch an immune attack against the recipient’s organs and tissues. The skin is the most frequently affected organ in chronic GVHD, involved in approximately 70 percent of patients who develop this condition.^[3]

Chronic GVHD typically appears more than 100 days after the transplant, though it can develop at any time. Unlike acute GVHD, which tends to happen shortly after transplant, chronic GVHD develops more slowly and can affect many more parts of the body. Some people develop chronic GVHD after having acute GVHD first, while others develop it without ever having acute symptoms.^[2]

The skin manifestations of chronic GVHD can be diverse and complex. The condition may cause skin thinning, changes in skin color, thick and tight skin, or spots on the skin. Beyond the skin surface, chronic GVHD can also affect the deeper layers of skin and the connective tissue beneath it, leading to scarring and hardening that can restrict movement and cause significant discomfort.^[3]

Epidemiology: How Common Is This Condition

Chronic GVHD is a widespread problem among transplant recipients. Studies show that it can affect between 40 and 60 percent of patients who undergo allogeneic stem cell transplantation, depending on various factors related to both the donor and the recipient.^[1] This makes it one of the most common long-term complications that transplant survivors face.

The incidence of chronic GVHD appears to vary based on the source of the stem cells used in the transplant. When peripheral blood stem cells are used rather than bone marrow, the risk of developing chronic GVHD tends to be higher. The use of peripheral blood stem cells has become more common in recent years, which may contribute to an increased number of people living with chronic GVHD.^[2]

Chronic GVHD accounts for a significant portion of deaths following transplant, with GVHD overall being responsible for about 15 percent of mortality after transplantation. This condition also has a substantial impact on quality of life, particularly because it can last for extended periods, sometimes years, and often requires prolonged treatment with medications that suppress the immune system.^[1]

While chronic GVHD is most strongly associated with allogeneic stem cell transplantation, it can also occur, though extremely rarely, after other types of procedures. These include transfusions of non-irradiated blood products, solid organ transplants, or even after autologous transplants where patients receive their own stem cells back.^[1]

The condition does not discriminate by age, though older age in either the donor or recipient is considered a risk factor for developing GVHD. The prevalence of chronic GVHD may actually be increasing over time as more people survive the immediate period after transplant and as transplants are being performed on older patients who previously would not have been considered candidates.^[13]

Causes and Risk Factors

The underlying cause of chronic GVHD is rooted in how the immune system functions after transplant. When a patient receives donor stem cells, those cells contain immune cells called T lymphocytes. These T lymphocytes are programmed to recognize and attack foreign substances. In chronic GVHD, these donor T lymphocytes mistakenly identify the patient’s own tissues as foreign and launch an immune attack against them.^[2]

The exact mechanisms that trigger chronic GVHD are complex and not fully understood. However, it is clear that the condition results from a complicated interaction between the donor’s immune cells and the recipient’s body. This immune reaction likely involves multiple pathways and factors that lead to both inflammation and the development of scar tissue, or fibrosis, in affected organs.^[5]

Several risk factors increase the likelihood that someone will develop chronic GVHD after transplant. The strongest predictor is a mismatch in human leukocyte antigens (HLA) between the donor and recipient. HLA are proteins on the surface of cells that help the immune system recognize what belongs in the body and what does not. Even when donors and recipients are closely matched, minor differences in other compatibility factors can still contribute to GVHD risk.^[1]

Age plays a significant role in risk. Both older donors and older recipients are more likely to experience chronic GVHD. Gender differences between donor and recipient also matter, with gender mismatch increasing risk. If a female donor has been pregnant or received blood transfusions in the past, this can further elevate the risk of GVHD in the recipient.^[2]

The type of stem cells used affects risk as well. Transplants using peripheral blood stem cells, which are collected from circulating blood rather than from bone marrow, carry a higher risk of chronic GVHD compared to bone marrow transplants. Patients who have had their spleen removed before transplant also face increased risk.^[2]

Symptoms: What Patients Experience

Chronic GVHD affecting the skin can cause a wide range of symptoms that significantly impact daily life. The symptoms can vary greatly from person to person, and their severity may change over time. Understanding these symptoms is important because the skin is often the first place where chronic GVHD becomes visible, making it an early warning sign of the condition.^[1]

One of the most common and distressing symptoms is intense itching, which can occur even before any visible skin changes appear. This itching can be severe enough to interfere with sleep and daily activities. Many patients describe the itching as constant and difficult to relieve with standard treatments.^[2]

The skin itself can undergo several types of changes. Some patients develop a condition called poikiloderma, where the skin shows a combination of changes including areas of darker and lighter pigmentation, making the skin appear mottled or patchy. The skin may become thinner in some areas or thicker in others. These changes in skin color and texture can affect how patients feel about their appearance and their self-esteem.^[2]

One of the most challenging aspects of chronic skin GVHD is the development of tight, thick skin that resembles scar tissue. This occurs because the immune attack leads to fibrosis, or the buildup of scar tissue in the skin and the tissues beneath it. When this happens, the skin loses its normal flexibility and elasticity. Patients may find that their skin feels stiff and restricted, especially over joints.^[3]

The thickening and tightening of the skin can lead to serious functional problems. When the skin becomes tight around joints like the fingers, wrists, elbows, or knees, it can limit range of motion. Simple tasks like opening a jar, typing on a keyboard, or walking may become difficult or painful. Some patients develop contractures, where joints become permanently bent because the surrounding tissue is so tight.^[2]

Chronic skin GVHD can also cause skin dryness and cracking. The skin may feel rough and flaky, and may crack easily, especially in areas that bend or experience friction. These cracks can be painful and can increase the risk of skin infections. The skin may also become more fragile and easily injured.^[3]

Hair changes are common with chronic GVHD. Patients may experience hair loss or thinning on the scalp, and in some cases, this hair loss can be permanent if it involves scarring. Body hair may also be lost. Some people develop scaly patches on the scalp or raised bumps. The scalp may feel tender or itchy.^[2]

Nail changes frequently occur alongside skin symptoms. The nails may develop vertical ridges or lines running from the base to the tip. They can become brittle and may split or chip easily. In more severe cases, nails may separate from the nail bed, a condition called onycholysis, or may be lost entirely. Some patients develop pterygium, where the skin at the base of the nail grows forward over the nail plate.^[2]

Beyond the physical symptoms, chronic skin GVHD often causes significant emotional and psychological distress. The visible changes to appearance, combined with chronic discomfort, can lead to feelings of depression and anxiety. Many patients report reduced vitality and struggle with the psychological stress of living with a chronic condition that may last for years.^[2]

Prevention Strategies

Preventing chronic GVHD is challenging, but several approaches are used to reduce the risk after transplant. The most important prevention strategy involves medications that suppress the immune system, given to all patients who undergo allogeneic stem cell transplantation. These medications aim to prevent the donor immune cells from attacking the recipient’s body.^[10]

The standard prevention approach involves using a medication called cyclosporine for approximately six months after transplant, often combined with short courses of another drug called methotrexate. When using cyclosporine, doctors monitor blood levels carefully to ensure they remain high enough to provide protection. Some transplant centers use tacrolimus instead of cyclosporine, particularly when the donor and recipient are unrelated, as it may offer better control of GVHD.^[10]

Another medication sometimes added to prevention regimens is prednisone, a type of steroid. While adding prednisone can reduce the incidence of GVHD, studies have not shown that it improves overall survival. This highlights an important aspect of GVHD prevention: reducing the occurrence of GVHD while maintaining the beneficial effects of the transplant is a delicate balance.^[10]

Some transplant centers use a substance called antithymocyte globulin (ATG) before the transplant. This treatment significantly reduces the risk of severe acute GVHD and extensive chronic GVHD. However, it does not appear to change overall survival rates, possibly because it increases the risk of infections by suppressing the immune system more broadly.^[10]

Researchers have explored removing T-cells from the donor stem cells before transplantation, a process called T-cell depletion. While this can reduce GVHD risk, it has not consistently improved survival compared to standard preventive treatments in patients receiving well-matched grafts. Other medications being studied for GVHD prevention include mycophenolate mofetil, sirolimus, and various other immune-modulating agents.^[10]

A specialized procedure called extracorporeal photopheresis (ECP) has been used as part of prevention strategies in some cases. In this procedure, a patient’s white blood cells are collected, treated with a light-sensitive drug, exposed to ultraviolet light, and then returned to the body. This makes the cells more likely to undergo programmed cell death, which can help regulate the immune response. ECP has shown promise when used as part of the conditioning regimen before transplant.^[10]

Beyond medical prevention, careful donor selection plays a crucial role. Finding donors who are as closely matched as possible in terms of HLA and other compatibility factors can reduce GVHD risk. However, even with the best matching, GVHD can still occur because of minor genetic differences between donor and recipient.^[1]

How Chronic GVHD Affects the Body: Pathophysiology

Understanding how chronic GVHD changes the normal functioning of the skin and underlying tissues helps explain why symptoms occur and why treatment can be challenging. The pathophysiology of chronic GVHD involves complex changes at multiple levels, from individual cells to entire organ systems.^[5]

In chronic GVHD, the donated immune cells create an imbalanced immune response. The body produces too many of certain inflammatory molecules and cells while not producing enough of others that normally help regulate and calm immune reactions. This imbalance leads to persistent inflammation throughout affected tissues. When inflammation continues for weeks, months, or even years, it causes ongoing damage to normal tissue structures.^[6]

One of the hallmark features of chronic GVHD is the development of fibrosis, or excessive scar tissue formation. In the skin, this fibrosis occurs when specialized cells called fibroblasts become overactive and produce too much collagen, the main structural protein in skin and connective tissue. As excessive collagen accumulates, the skin becomes thick, tight, and loses its normal flexibility. This process can extend beyond the skin into the deeper tissues, including the layer of connective tissue that surrounds muscles, called fascia.^[7]

The inflammatory process in chronic GVHD involves multiple types of immune cells and molecules. T lymphocytes from the donor recognize proteins on the recipient’s cells as foreign. This recognition triggers a cascade of immune responses, including the release of chemical messengers called cytokines. These cytokines attract more immune cells to the area and promote inflammation. Some cytokines specifically promote fibrosis by stimulating fibroblasts to produce more collagen.^[7]

Chronic skin GVHD affects different layers of the skin in distinct ways. The outermost layer, or epidermis, may become thinner as cells in this layer are damaged or lost. The middle layer, or dermis, typically shows signs of inflammation and increased collagen deposition. Changes can also occur in the small blood vessels within the skin, affecting blood flow and contributing to color changes visible on the skin surface.^[3]

The damage to skin structures extends to specialized components like hair follicles and sweat glands. When these structures are damaged by the inflammatory process, they may be permanently lost, leading to persistent hair loss and problems with skin moisture and temperature regulation. The nail matrix, where nail cells are produced, can also be affected, leading to the nail abnormalities commonly seen in chronic GVHD.^[2]

Chronic GVHD also involves changes in how the body regulates immune responses. Normally, the immune system has built-in mechanisms to prevent excessive reactions and to calm inflammation once a threat is eliminated. In chronic GVHD, these regulatory mechanisms appear to be impaired. Certain types of immune cells that normally suppress excessive immune responses may not function properly or may be present in insufficient numbers.^[13]

The changes occurring in chronic GVHD share similarities with certain autoimmune diseases, where the body’s immune system attacks its own tissues. For example, the skin changes in chronic GVHD can resemble those seen in scleroderma, a condition characterized by skin thickening and fibrosis. The mouth changes can look similar to lichen planus, an inflammatory condition affecting mucous membranes. This overlap makes diagnosis challenging at times and provides clues about the underlying mechanisms of chronic GVHD.^[1]

One important aspect of chronic GVHD pathophysiology is that the condition involves not just tissue damage but also attempts at tissue repair. However, these repair processes become dysregulated, leading to excessive scarring rather than normal healing. Understanding this aspect has helped researchers identify potential new treatment approaches that target the fibrotic process specifically.^[7]

The duration and persistence of chronic GVHD relates to its pathophysiology. Unlike acute GVHD, which tends to resolve or be controlled relatively quickly with treatment, chronic GVHD can persist for months to years. The average duration is between one and three years, but some patients experience symptoms for much longer. This prolonged course reflects the self-perpetuating nature of the inflammatory and fibrotic processes that characterize chronic GVHD.^[12]